TY - JOUR
T1 - Zolav®: a new antibiotic for the treatment of acne
AU - Dinant, A
AU - Boulos, Ramiz
PY - 2016/3/22
Y1 - 2016/3/22
N2 -
Background: Acne is a prominent skin condition affecting >80% of teenagers and young adults and ~650 million people globally. Isotretinoin, a vitamin A derivative, is currently the standard of care for treatment. However, it has a well-established teratogenic activity, a reason for the development of novel and low-risk treatment options for acne. Objective: To investigate the effectiveness of Zolav®, a novel antibiotic as a treatment for acne vulgaris. Materials and methods: Minimum inhibitory concentration of Zolav® against Propionibacterium acnes was determined by following a standard protocol using Mueller-Hinton broth and serial dilutions in a 96-well plate. Cytotoxicity effects on human umbilical vein endothelial cells and lung cells in the presence of Zolav® were investigated by determining the growth inhibition (GI
50
) concentration, total growth inhibition concentration, and the lethal concentration of 50% (LC
50
). The tryptophan auxotrophic mutant of Escherichia coli strain, WP2 uvrA (ATCC 49979), was used for the AMES assay with the addition of Zolav® tested for its ability to reverse the mutation and induce bacterial growth. The in vivo effectiveness of Zolav® was tested in a P. acnes mouse intradermal model where the skin at the infection site was removed, homogenized, and subjected to colony-forming unit (CFU) counts. Results: Susceptibility testing of Zolav® against P. acnes showed a minimum inhibitory concentration of 2 μg/mL against three strains with no cytotoxicity and no mutagenicity observed at the highest concentrations tested, 30 μM and 1,500 μg/plate, respectively. The use of Zolav® at a concentration of 50 μg/mL (q8h) elicited a two-log difference in CFU/g between the treatment group and the control. Conclusion: This study demonstrates the potential of Zolav® as a novel treatment for acne vulgaris.
AB -
Background: Acne is a prominent skin condition affecting >80% of teenagers and young adults and ~650 million people globally. Isotretinoin, a vitamin A derivative, is currently the standard of care for treatment. However, it has a well-established teratogenic activity, a reason for the development of novel and low-risk treatment options for acne. Objective: To investigate the effectiveness of Zolav®, a novel antibiotic as a treatment for acne vulgaris. Materials and methods: Minimum inhibitory concentration of Zolav® against Propionibacterium acnes was determined by following a standard protocol using Mueller-Hinton broth and serial dilutions in a 96-well plate. Cytotoxicity effects on human umbilical vein endothelial cells and lung cells in the presence of Zolav® were investigated by determining the growth inhibition (GI
50
) concentration, total growth inhibition concentration, and the lethal concentration of 50% (LC
50
). The tryptophan auxotrophic mutant of Escherichia coli strain, WP2 uvrA (ATCC 49979), was used for the AMES assay with the addition of Zolav® tested for its ability to reverse the mutation and induce bacterial growth. The in vivo effectiveness of Zolav® was tested in a P. acnes mouse intradermal model where the skin at the infection site was removed, homogenized, and subjected to colony-forming unit (CFU) counts. Results: Susceptibility testing of Zolav® against P. acnes showed a minimum inhibitory concentration of 2 μg/mL against three strains with no cytotoxicity and no mutagenicity observed at the highest concentrations tested, 30 μM and 1,500 μg/plate, respectively. The use of Zolav® at a concentration of 50 μg/mL (q8h) elicited a two-log difference in CFU/g between the treatment group and the control. Conclusion: This study demonstrates the potential of Zolav® as a novel treatment for acne vulgaris.
KW - Acne
KW - Antibiotic resistance
KW - Benzoyl peroxide
KW - Isotretinoin
KW - MscL
KW - Zolav®
UR - https://doi.org/10.2147/DDDT.S106462
UR - http://www.scopus.com/inward/record.url?scp=84961654841&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S106462
DO - 10.2147/DDDT.S106462
M3 - Article
VL - 10
SP - 1235
EP - 1242
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
SN - 1177-8881
ER -